相关实验视频

Updated: Jun 13, 2025

Techniques to Induce and Quantify Cellular Senescence

Techniques to Induce and Quantify Cellular Senescence

Published on: May 1, 2017

探索肺腺癌中细胞衰老的分子和免疫景观

Kun Ru¹, Liang Cui², Cong Wu¹

¹Department of Pathology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.

Frontiers in immunology

|September 13, 2024

概括

这项研究开发了一种新的与衰老相关的肺腺癌 (LUAD) 预后模型,使用了10个与衰老相关的基因 (ARG). 较低的衰老得分与更好的生存率和免疫激活相关,突出显示ARG是LUAD的预后生物标志物.

科学领域:

在瘤学瘤学.
免疫学免疫学免疫学
遗传学遗传学是一种遗传学.

背景情况:

细胞衰老和癌症之间的联系,特别是肺腺癌 (LUAD),是复杂的.
以前的研究表明,LUAD细胞衰老与免疫反应之间存在联系,但缺乏单细胞验证.
细胞衰老在癌症的发展和进展中起着至关重要的作用.

研究的目的:

开发和验证基于与衰老相关的基因 (ARG) 的LUAD新型预后模型.
研究细胞衰老,基因组变化和LUAD中的免疫微环境之间的关系.
分析LUAD瘤微环境 (TME) 中衰老和细胞间通信的异质性.

主要方法:

整合了来自GenAge和CellAge数据库的衰老基因.
采用LASSO Cox分析来构建和验证ARG预后模型.
分析了单细胞转录组数据,以评估LUAD中的衰老异质性和免疫细胞透.

主要成果:

一个10基因ARG风险模型被开发和验证为LUAD的独立预后预测器.
低衰老得分 (LAS组) 的患者表现出更好的生存率,更低的瘤突变负担 (TMB) 和增强的免疫激活.
高衰老得分 (HAS) 组表现出瘤细胞丰富的增加,免疫细胞透的减少,以及免疫逃生通路的丰富 (SPP1,TENASCIN).

结论:

开发的ARG风险评分 (ARRS) 是预测LUAD预后的强有力的生物标志物.
细胞衰老显著影响LUAD瘤微环境和免疫格局.
准细胞衰老途径可能为LUAD提供治疗策略.

关键词:

细胞衰老细胞衰老不同质性的异质性肺部腺癌的癌症.机器学习是机器学习.瘤微环境是一个微环境.

更多相关视频

A Quantitative Measurement of Reactive Oxygen Species and Senescence-associated Secretory Phenotype in Normal Human Fibroblasts During Oncogene-induced Senescence

A Quantitative Measurement of Reactive Oxygen Species and Senescence-associated Secretory Phenotype in Normal Human Fibroblasts During Oncogene-induced Senescence

Published on: August 12, 2018

Induction and Validation of Cellular Senescence in Primary Human Cells

Induction and Validation of Cellular Senescence in Primary Human Cells

Published on: June 20, 2018

相关概念视频

PI3K/mTOR/AKT Signaling Pathway

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...